LymphomaArchives
Targeting the CD47/SIRPα interaction in cancer: opportunities in non-Hodgkin lymphoma
Lymphoma 1 min.
Macrophages are attractive targets for novel cancer immunotherapy approaches since they can infiltrate into the tumor microenvironment and have the capacity to engulf and destroy cancer cells by phagocytosis. The CD47/SIRPα axis is a key immune checkpoint that regulates macrophages' ability to...
Allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT-lymphoma working party
Lymphoma 5 min.
T-cell lymphomas comprise a heterogeneous group of malignancies derived from mature T-cells accounting for around 10% of all lymphomas diagnosed in the Western world [1]. The most frequent non-cutaneous, non-leukemic T-cell lymphoma entities are peripheral T-cell lymphoma not otherwise specified (PTCL...
Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis
Lymphoma 1 min.
Bridging radiation therapy (BRT) is increasingly utilized prior to CD19-directed chimeric antigen receptor T cells (CART19) in patients with non-Hodgkin lymphoma (NHL). However, its impact on outcomes of CART19 therapy is not established. We conducted a systematic review and meta-analysis to estimate...
Complete remission of bronchus-associated lymphoid tissue lymphoma after antibiotic treatment forTropheryma whipplei
Lymphoma 1 min.
Extranodal marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) is an indolent lymphoma that accounts for approximately 7-8% of newly diagnosed lymphomas. MALT lymphoma most commonly originates from the stomach while extra-gastric MALT lymphoma is located most frequently in...
